Local study shows potential benefits of Xolair in treating asthma patients

Interim data presented recently at the joint congress that Xolair (omalizumab) for Subcutaneous Use significantly reduced asthma attacks in 23 Korean patients with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. The study further defines the safety profile of Xolair in this patient population.

The study, which has been conducted in 11 local...